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arkers of
ctivated Coagulation in
cute Coronary Syndromes*
ens Peter Goetze, MD, DMSC
openhagen, Denmark
dentification of potentially useful bloodborne markers in
cute coronary syndromes (ACS) is steadily increasing. The
linical applications range from prediction and prognosis to
efinition and diagnosis. In the center of the markers stand
he myocardial proteins and enzymes, because their presence
n the circulation reflects myocardial damage and myocyte
eath (1). Their concentrations mirror the myocardial lesion
ize and, accordingly, provide information on the following
rognosis. At the other end of the concentration scale are
mproved and sensitive methods that may provide new insight
nto the clinical relevance of even very low concentrations.
or the individual patient, the concentrations therefore
uide therapy directly (diagnosis) and indirectly (risk).
See page 2422
Most of the new markers are not included in the present
ecommendations for ACS. Several markers appear quite
romising, and it may just be a matter of time before they
re included in the biochemical evaluation of ACS. One
uch marker complex could be the cardiac-derived natri-
retic peptides. Their release is a dynamic response, which
ven brings about the attractive concept that the peptides
ay be used to monitor reversible pathology rather than
nly the consequence of myocyte death. In this respect,
easurement of cardiac-derived peptides in patients with
CS provides important prognostic information and may
elp the clinician in identifying patients at high risk of
urther morbidity and death (2). The underlying mechanism
s not completely elucidated but appears to relate to changes
n myocardial function or intermittent hypoxic conditions in
he heart muscle—or both (3).
A thrombotic process precedes myocardial damage and
ltered heart function in patients with ACS. Obviously, the
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.f
From the Department of Clinical Biochemistry, Rigshospitalet, University of
openhagen, Copenhagen, Denmark.ause of disease is not in the heart muscle but in the
oronary vasculature and is sometimes referred to as athero-
hrombosis. Atherothrombosis combines the low-grade but
ong-term lipid accumulation and vascular inflammation
years) with the subacute thrombotic build-up and symptom-
ausing occlusion (days). It therefore seems to be a logical
ite to search for new markers in ACS. In this issue of the
ournal, Mega et al. (4) report on thrombus precursor
rotein (TpP) as a predictor in patients presenting with
CS. By TpP measurements in stored plasma from the
PUS–TIMI 16 (Oral Glycoprotein IIb/IIIa Inhibition
ith Orbofiban in Patients With Unstable Coronary
yndromes–Thrombolysis In Myocardial Infarction 16) trial,
he authors report an approximately 2-fold TpP increase in
CS patients compared with healthy control subjects and that
n increased concentration was prognostic for later death,
yocardial infarction, or recurrent ischemia within the ACS
atient group. The TpP concentrations only correlated weakly
ith other known markers in ACS, such as troponin I,
igh-sensitivity C-reactive protein, or B-type natriuretic pep-
ide. In multivariable analysis, TpPmeasurement still remained
rognostic, with hazard ratios of approximately 1.5 for later
eath or myocardial infarction.
The authors are to be congratulated for focusing on the
hrombotic process in ACS. As such, the present study
hould stimulate further research into both TpP and other
elated markers of fibrin formation and thrombosis. Con-
eptually, the authors argue that a marker of activated
hrombosis could contain useful information with regard to
he ongoing thrombotic process in ACS. Several earlier
tudies corroborate that this may indeed be the case as, for
nstance, the concentrations of fibrinogen, soluble fibrin,
nd—at the other end of fibrin generation—the fibrinolytic
athway represented by the plasminogen activator inhibitor-1,
re all associated with the risk of myocardial infarction (5–7).
or these markers, however, it is not clear whether they
eflect the low-grade but long-term inflammatory pathology
n atherosclerosis or whether the concentrations also can be
egarded as active features in the subacute thrombus forma-
ion in ACS. Notably, none of the former markers appear to
ossess enough clinical information to be included in an
ssessment of risk and prognosis in individual ACS patients.
ther fibrin-related markers have also been tested. D-dimer
easurement, for which most laboratories nowadays pro-
ide a routine analysis, seems to provide a similar perfor-
ance to the present TpP marker (8). More coagulation
arkers have also been examined in ACS, and the findings
ave usually been suggestive of general associations but not
uitable for individual patient assessment (9).
Several inherent troubles haunt the markers of coagula-
ion in ACS. First, there is an obvious need for a better
nderstanding of the causative mechanisms. Many of the
arkers are also associated with the inflammatory athero-
clerotic process rather than just the subacute thrombus
ormation. This may also apply to TpP, and studies will be
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June 24, 2008:2430–1 Editorial Commenteeded to address whether the 2-fold increase in TpP is
ndeed specific to ACS or just a feature of general illness or
nflammation. Acute disease causes a general prothrombotic
tate, which is reflected in several coagulation analyses, includ-
ng “global” coagulation tests such as thromboelastography.
Second, the coronary thrombus in patients with ACS is
hysically quite small, and the potential markers of activated
oagulation need to be very sensitive and possibly somewhat
etter than detecting the much larger venous thrombi. In
he present report on TpP concentrations, this matter is left
bit unclear, as more severe ACS (ST-segment elevation
yocardial infarction vs. unstable angina pectoris) was in
act associated with lower TpP concentrations. Such a
arker profile may be tricky to make everyday decision
imits for, because the relation to severity of disease is not
traightforward. Essentially, the least and the most ill
atient can have the same TpP concentration, and how is
he clinician to extrapolate rational actions in this situation?
Third, patients with ACS are promptly treated with
rugs that interfere with the coagulation process and
lso—to some extent—the coagulation analyses. Thus, the
ime of blood sampling for analysis becomes critically
mportant. To that end, the use of catheter-guided therapy
hould also be considered here, because balloon inflation at
he very site of occlusion is likely to affect the local
iochemistry of the thrombus. Finally, the markers of
oagulation can be a challenge from an analytical point of
iew. Measurement of fibrinogen and D-dimer is still not a
traightforward matter, and different methods produce quite
ifferent results. For TpP, the assay issues are not yet well
haracterized, and more data on pre-analytical pitfalls and
nalytical details will be needed before the analysis can be
ntroduced in routine laboratories. Moreover, although the
heory may advocate for TpP measurement as a marker of
ctivated coagulation, it still needs to be put to the test
hether traditional markers of coagulation are actually
eporting on the very same phenomenon. Head-to-head
tudies that use all putative markers in play should be
erformed. The increasing number of markers for predic-
ion and prognosis in ACS could perhaps lead one to
peculate that good clinical judgment may one day be
eplaced with risk charts based on various markers and
erhaps even in a multimarker approach. After all, objective
easurements “don’t lie” and can easily be validated and
tandardized. However, in reality, the identification of
arkers with only modest clinical performances underscoreshe need for robust clinicians who can safely guide theatients through the vast load of information (and disinfor-
ation) based on median values derived from large clinical
tudies from the past. Hard clinical data such as patient age,
moking habits, and comorbidities such as diabetes, obesity,
nd hypertension still beat most biochemistry.
Thus, the modern cardiologist should probably remain
eluctant in the adoption of new markers for prediction and
rognosis. Even if applying some of the markers, the
linician will have to serve as an academic translator of all of
he information. All patients are different, and with hazard
atios of only 1.5, it is likely that some patients will be
armed by unreasonable clinical decisions if the same
ctions are to be introduced based on such assessments. To
ut it on the line, patients may even be “lost in translation”
f introducing multiple markers in a complex syndrome like
CS. Markers of activated coagulation are not likely to
ake this any easier for patients and clinicians.
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